Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases

被引：98

作者：

Bardotti, Angela ^{[1
]}

Averani, Giovanni ^{[1
]}

Berti, Francesco ^{[1
]}

Berti, Stefania ^{[1
]}

Carinci, Valeria ^{[1
]}

D'Ascenzi, Sandro ^{[1
]}

Fabbri, Barbara ^{[1
]}

Glannini, Sara ^{[1
]}

Giannozzi, Aldo ^{[1
]}

Magagnoli, Claudia ^{[1
]}

Proietti, Daniela ^{[1
]}

Norelli, Francesco ^{[1
]}

Rappuoli, Rino ^{[1
]}

Ricci, Stefano ^{[1
]}

Costantino, Paolo ^{[1
]}

机构：

[1] Novartis Vaccines & Diagnost Srl, I-53100 Siena, Italy

来源：

VACCINE | 2008年 / 26卷 / 18期

关键词：

glycoconjugate vaccines; physicochemical characterisation; Neisseria meningitidis;

D O I：

10.1016/j.vaccine.2008.01.022

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Bacterial capsular polysaccharides covalently linked to an appropriate carrier protein represent the best tool. to induce a protective immune response against a wide range of bacterial diseases, such as meningococcal infections. We describe here the physico-chemical characterisation of glycoconjugate molecules designed to prepare a vaccine against Neisseria meningitidis serogroups A, C, W135 and Y. The use of a selective conjugation chemistry resulted in well. characterised, reproducible and traceable glycoconjugate that can be consistently manufactured at large scale. A pool of physical and spectroscopic methods was used to establish glycosylation ratio, identity, molecular weight profiles, integrity of carrier protein and sites of glycosylation, assuring effective and consistent lots of vaccines. (C) 2008 Published by Elsevier Ltd.

引用

页码：2284 / 2296

页数：13

共 30 条

[1] ANDERSON PW, 1989, J IMMUNOL, V142, P2464
[2] Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against Neisseria meningitidis groups Y and W135
Bardotti, A
Averani, G
Berti, F
Berti, S
Galli, C
Giannini, S
Fabbri, B
Proietti, D
Ravenscroft, N
Ricci, S
[J]. VACCINE, 2005, 23 (16) : 1887 - 1899
[3] REFINED STRUCTURE OF MONOMERIC DIPHTHERIA-TOXIN AT 2.3-ANGSTROM RESOLUTION
BENNETT, MJ
EISENBERG, D
[J]. PROTEIN SCIENCE, 1994, 3 (09) : 1464 - 1475
[4] Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses
Berry, DS
Lynn, F
Lee, CH
Frasch, CE
Bash, MC
[J]. INFECTION AND IMMUNITY, 2002, 70 (07) : 3707 - 3713
[5] Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines
Costantino, P
Norelli, F
Giannozzi, A
D'Ascenzi, S
Bartoloni, A
Kaur, S
Tang, DZ
Seid, R
Viti, S
Paffetti, R
Bigio, M
Pennatini, C
Averani, G
Guarnieri, V
Gallo, E
Ravenscroft, N
Lazzeroni, C
Rappuoli, R
Ceccarini, C
[J]. VACCINE, 1999, 17 (9-10) : 1251 - 1263
[6] DEVELOPMENT AND PHASE-1 CLINICAL-TESTING OF A CONJUGATE VACCINE AGAINST MENINGOCOCCUS-A AND MENINGOCOCCUS-C
COSTANTINO, P
VITI, S
PODDA, A
VELMONTE, MA
NENCIONI, L
RAPPUOLI, R
[J]. VACCINE, 1992, 10 (10) : 691 - 698
[7] Comparison of the diphtheria mutant toxin, CRM197, with a Haemophilus influenzae type-b polysaccharide CRM197 conjugate by optical spectroscopy
Crane, DT
Bolgiano, B
Jones, C
[J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 246 (02): : 320 - 327
[8] Bacterial polysaccharide-protein conjugate vaccines
Finn, A
[J]. BRITISH MEDICAL BULLETIN, 2004, 70 (01) : 1 - 14
[9] GIANNINI G, 1984, NUCLEIC ACIDS RES, V12, P4063, DOI 10.1093/nar/12.10.4063
[10] Prospects for vaccine prevention of meningococcal infection
Harrison, LH
[J]. CLINICAL MICROBIOLOGY REVIEWS, 2006, 19 (01) : 142 - +

← 1 2 3 →